Scientists in the US say they have developed molecules to drill holes into antibiotic-resistant bacteria. Their nanomachines were activated by light and found to increase the susceptibility of drug-resistant Klebsiella pneumoniae to meropenem.
A new antibiotic holds promise for the treatment of Clostridium difficile infections (CDIs). Phase 2 clinical trials by UK drug discovery company Summit Therapeutics show the antibiotic ridinilazole significantly outperforms the current treatment: vancomycin.
In late December 2019, US antibiotic maker Melinta was forced into bankruptcy.
UK life science company Abcam, headquartered in Cambridge, and University College London spinout SomaServe have joined forces to commercialise the latter’s polymer-based ‘bioic’ nanoparticles which can carry a range of products to live cells.
Imagine being able to eat a juicy burger, while knowing that no animals were harmed in its production. That vision may soon be a reality, thanks to a range of companies growing meat in a lab, Jasmin Fox Skelly reports
Maria Burke reports on the warning that the world faces an ‘imminent crisis’ in phosphate availability, a critical fertiliser that underpins the world’s food supply
European demand for polypropylene (PP) compounds has stalled since the middle of 2018; caused by mounting issues in the automotive industry.
Many observers believe that industry is making the running in terms of combatting climate change.
A cyanine dye that binds a subset of CSCS - The last paper highlighted in the Biomedical section in December 2019 (C&I, 2019, 11, 43) described a peptoid derivative that binds a sub-set of cancer stem cells (CSCs), apparently via the plectin protein (Science Reports, 2019, 9, 14954).